Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 49Rectal Neoplasms 29Pancreatic Neoplasms 25Colonic Neoplasms 25Neoplasm Metastasis 19Stomach Neoplasms 17Neoplasms 17Esophageal Neoplasms 17Head and Neck Neoplasms 12Squamous Cell Carcinoma of Head and Neck 10Breast Neoplasms 10Adenocarcinoma Of Esophagus 8Esophageal Squamous Cell Carcinoma 6Cholangiocarcinoma 6Carcinoma, Squamous Cell 6Gallbladder Neoplasms 5Carcinoma, Hepatocellular 5Bile Duct Neoplasms 5Liver Neoplasms 4Anus Neoplasms 4Lung Neoplasms 3Triple Negative Breast Neoplasms 2Somatostatinoma 2Sarcoma 2Peritoneal Neoplasms 2Mouth Neoplasms 2Melanoma 2Lymphoma, Non-Hodgkin 2Leukemia, Myeloid, Acute 2Leukemia, Lymphocytic, Chronic, B-Cell 2

Interventions

Radiotherapy 1Oxaliplatin 1Lapatinib 1Fluorouracil 1Combined Modality Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × HER2 Positive Esophagogastric Cancer × Fluorouracil × Clear all
NCT01769508 2016-06-13

Study of 5-FU, Oxaliplatin, & Lapatinib Combined With Radiation Therapy to Treat HER2 Positive Esophagogastric Cancer

SCRI Development Innovations, LLC

Phase 2 Terminated
12 enrolled 8 charts
Gastrointestinal

HER2 Positive Esophagogastric Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡